- Home
- OPAD vs ICCM Comparison
OPAD vs ICCM Comparison
Compare OPAD & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | OPAD | ICCM |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | Israel |
| Employees | 140 | N/A |
| Industry | Real Estate | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4M | 20.4M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | OPAD | ICCM |
|---|---|---|
| Price | $5.32 | $5.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $1.83 | ★ $2.50 |
| AVG Volume (30 Days) | 216.4K | ★ 8.4M |
| Earning Date | 04-30-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $139.51 |
| Revenue Next Year | $32.08 | $75.66 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.13 |
| 52 Week High | $6.35 | $9.54 |
Technical Indicators
Market Signals| Indicator | OPAD | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 75.68 | 56.84 |
| Support Level | $0.63 | $0.62 |
| Resistance Level | $5.53 | $5.69 |
| Average True Range (ATR) | 0.40 | 1.53 |
| MACD | -0.03 | -0.11 |
| Stochastic Oscillator | 80.80 | 43.67 |
Price Performance
Historical ComparisonAbout OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services, including mortgage, listing, renovation, and buyer representation services.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.